VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Jinglong Guo, Siddheshvar Bhela, Monica Sharma et al. · Cancer Immunology Research · 2026
Immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC), yet their response rates remain limited, highlighting the need for new therapeutic targets. In this study, we found that V-set and immunoglobulin domain-containing 4 (VSIG4) is predominantly expressed by macrophages in both mouse and human HCC, with high VSIG4 expression correlating with poor prognosis in patients with HCC. In autochthonous HCC models, VSIG4 deficiency in mice promoted tumor-specific CD8+ T-cell abundance, intratumoral infiltration, and effector function in the tumor microenvironment, resulting in better tumor control and significantly enhanced efficacy of anti-PD-L1 and anti-VEGF combination treatments. Furthermore, we observed that VSIG4+ macrophages colocalize with CD8+ T cells in HCC and that VSIG4 directly mediates T cell suppression in ex vivo and in vitro studies. These findings suggest that VSIG4 is a critical inhibitor of antitumor immunity in HCC and may be targeted for improved immunotherapies.
Cited by 2 works. doi:10.1158/2326-6066.cir-25-0836
Authors
- Jinglong Guo
- Siddheshvar Bhela
- Monica Sharma
- Giulia Protti
- Shiuh-Ming Luoh
- Siyue Wang
- Natalie S. Firmino
- Dragos Dasoveanu
- Caleb K. Chan
- Veronica Ibarra-Lopez
- Conrad Foo
- Rajiv Jesudason
- Sandra Rost
- Tina Scholl
- James M. Ziai
- Laëtitia Comps‐Agrar
- Yulei Wang
- Sören Müller
- Andréy S. Shaw
- Jing Li
References
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
- Resolving the fibrotic niche of human liver cirrhosis at single-cell level
- A single-cell transcriptomic atlas characterizes ageing tissues in the mouse
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
- Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma